Clene's Nanocrystal ALS Treatment Bounces Back with Positive Data

Published: Mar 09, 2023 By Kate Goodwin

 

Pictured: Clene CEO Rob Etherington/company courtesy

Despite missing the initial mark, Clene Inc.’s gold nanocrystal therapy for ALS still shows promise. Thursday, the company shared new results from an exploratory analysis showing CNM-Au8 delayed disease progression across key areas for patients.

In October 2022, Clene reported that CNM-Au8 did not meet the primary endpoint of slope of change in the HEALEY ALS trial based on the adjusted ALS Functional Rating Scale-Revised.

However, the strong survival signals seen at six months warranted a deeper look.

 Original article

Comments

Popular posts from this blog

First map of every neuron in an adult brain has been produced for a fruit fly

Research finds resin that destroys coronavirus on plastic surfaces

Engineered Rabies Virus Illuminates Neural Circuitry